Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Jublia Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Jublia (efinaconazole) Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for topical Jublia (efinaconazole) used to treat qualifying toenail onychomycosis. It applies to providers submitting requests to Ventura County Health Care Plan.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyJublia (efinaconazole) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateAug 18, 2020
    Last ReviewFeb 18, 2025
    Next Review DateN/A
    Key ActionDocument failure, contraindication, or intolerance to two of itraconazole, oral terbinafine, and ciclopirox before requesting Jublia approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    48 weeksMaximum treatment course
    2 of 3Prior antifungal agents required
    12 weeksMinimum prior treatment duration
    ≤50%Maximum toenail involvement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial Therapy Criteria

    Jublia is approved when all of the following criteria are met.

    Initial therapy criteria

    • Qualifying fungal infection

      • Trichophyton rubrum: Diagnosis is confirmed as infection with Trichophyton rubrum.
      • Trichophyton mentagrophytes: Diagnosis is confirmed as infection with Trichophyton mentagrophytes.
    • Medical necessity: Treatment is requested due to a medical condition and not for cosmetic purposes.

      Examples include cellulitis risk associated with toenail onychomycosis or pain/discomfort from the infected nail.

    • Prior antifungal therapy

      • Itraconazole: Failure, contraindication, or intolerance to itraconazole, with a minimum 12-week treatment when trialed.≥12 weeks

        Generic Sporanox.

      • Oral terbinafine: Failure, contraindication, or intolerance to oral terbinafine, with a minimum 12-week treatment when trialed.≥12 weeks

        Generic Lamisil.

      • Ciclopirox: Failure, contraindication, or intolerance to ciclopirox, with a minimum 12-week treatment when trialed.≥12 weeks

        Generic Penlac.

    Subsequent Course Criteria

    For a subsequent course of therapy, a new test must be performed.

    Subsequent course diagnostic confirmation: A new diagnostic test confirms qualifying toenail onychomycosis due to Trichophyton rubrum or Trichophyton mentagrophytes before a subsequent course of Jublia is authorized.New test required

    Molecular diagnostic testing may be used; fungal culture is also referenced as a diagnostic method.

    Jublia is not covered when requested solely for cosmetic purposes. Treatment must address a documented medical condition and be medically necessary.

    Jublia is not medically necessary without a documented relevant condition, such as cellulitis risk associated with toenail onychomycosis or pain or discomfort from the infected nail.

    Clinical Coding Details

    Toenail involvement
    Maximum nail involvementNo more than 50% of the toenail
    Matrix involvementThe matrix must be spared
    Lunula involvementThe lunula must be spared
    Prior antifungal treatment duration
    ItraconazoleMinimum 12-week treatment
    Oral terbinafineMinimum 12-week treatment
    CiclopiroxMinimum 12-week treatment

    Provider Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Jublia. Approval depends on submission of documentation demonstrating that all listed coverage criteria are met.

    • Submit medical records supporting diagnostic confirmation, medical necessity, and qualifying prior antifungal treatment history.
    • For an approved course, apply to affected toenail(s) once daily for 48 weeks with complete coverage of the toenail, folds, bed, surrounding skin, and undersurface of the nail plate.
    Step Therapy

    Two Prior Antifungal Therapies Required

    Document failure, contraindication, or intolerance to two qualifying antifungal agents, subject to the minimum treatment durations specified by the plan.

    • Itraconazole (generic Sporanox): minimum 12-week treatment.
    • Oral terbinafine (generic Lamisil): minimum 12-week treatment.
    • Ciclopirox (generic Penlac): minimum 12-week treatment.

    Unsupported block type: documentation

    Documentation Required

    Medical Necessity Documentation

    Document that treatment is requested because of a medical condition and is medically necessary, not cosmetic.

    • Examples include a history of lower-extremity cellulitis with ipsilateral toenail onychomycosis.
    • Patients with diabetes must have additional risk factors for cellulitis.
    • Pain or discomfort associated with the infected nail supports medical necessity.

    Unsupported block type: documentation

    Denial Risk

    Cosmetic-Only Treatment Is Not Covered

    Requests for treatment solely for cosmetic purposes are not approvable. The submission must connect treatment to a documented medical condition or symptom.

    • Do not submit cosmetic improvement alone as the medical-necessity rationale.
    • Include the applicable risk of cellulitis or documented pain/discomfort associated with the infected nail.
    Denial Risk

    Denial Risk: Inadequate Confirmation or Treatment History

    Requests may be denied when the diagnosis, causative organism, or qualifying prior treatment history is not adequately confirmed. Missing documentation of failure, contraindication, or intolerance to two required antifungal agents also creates a denial risk.

    • Confirm toenail onychomycosis and infection with Trichophyton rubrum or Trichophyton mentagrophytes.
    • Document two qualifying prior agents, required treatment durations, trial dates, and outcomes.
    • Do not rely on an unconfirmed diagnosis or incomplete treatment history.
    Documentation Required

    New Diagnostic Test for Subsequent Course

    When Jublia is requested for a subsequent course of therapy, submit a new diagnostic test confirming the qualifying infection. Prior test results alone do not satisfy this requirement.

    • The new test must support toenail onychomycosis caused by Trichophyton rubrum or Trichophyton mentagrophytes.
    • Molecular diagnostic testing may be used; fungal cultures may have a longer turnaround time.

    Medication Background

    Jublia (efinaconazole) is a topical azole antifungal that inhibits fungal lanosterol 14-alpha-demethylase, an enzyme involved in ergosterol biosynthesis.

    Qualifying Diagnosis

    Qualifying distal subungual onychomycosis
    ConditionDistal subungual onychomycosis of the toenail
    Nail involvementInvolving no more than 50% of the nail
    Matrix and lunulaSparing the matrix and lunula

    Initial Jublia Authorization

    Initial Jublia Authorization

    Jublia will be approved when all authorization criteria are met.

    Initial authorization criteria

    • Qualifying fungal infection

      • Trichophyton rubrum: Diagnosis is confirmed as infection with Trichophyton rubrum.
      • Trichophyton mentagrophytes: Diagnosis is confirmed as infection with Trichophyton mentagrophytes.
    • Medical necessity: Treatment is requested due to a medical condition and not for cosmetic purposes.

      Examples include a history of lower-extremity cellulitis with ipsilateral toenail onychomycosis, diabetes with additional cellulitis risk factors, or pain/discomfort associated with the infected nail.

    • Prior antifungal therapy

      • Itraconazole: Failure, contraindication, or intolerance to itraconazole, with a minimum 12-week treatment when trialed.≥12 weeks

        Generic Sporanox.

      • Oral terbinafine: Failure, contraindication, or intolerance to oral terbinafine, with a minimum 12-week treatment when trialed.≥12 weeks

        Generic Lamisil.

      • Ciclopirox: Failure, contraindication, or intolerance to ciclopirox, with a minimum 12-week treatment when trialed.≥12 weeks

        Generic Penlac.

    Subsequent Course Authorization

    Subsequent Course Authorization

    For a subsequent course of therapy, a new test must be performed.

    New diagnostic test: A new test confirms qualifying toenail onychomycosis due to Trichophyton rubrum or Trichophyton mentagrophytes before continuation or repeat therapy with Jublia is authorized.New test required

    Required Prior Therapy

    StepRequired prior antifungal therapyDocumentation requirementMinimum duration
    1Trial two of: itraconazole, oral terbinafine, or ciclopiroxDocument failure, contraindication, or intolerance and the date of each trial12 weeks for each applicable treatment

    Treatment Duration and Administration

    Jublia quantity limit
    MedicationJublia (efinaconazole)
    Application frequencyApply once daily
    Treatment duration48 weeks
    Application siteAffected toenail(s)
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyJublia (efinaconazole) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateAug 18, 2020
    Last ReviewFeb 18, 2025
    Next Review DateN/A
    Key ActionDocument failure, contraindication, or intolerance to two of itraconazole, oral terbinafine, and ciclopirox before requesting Jublia approval.
    SourceLink
    On This Page
    Coverage CriteriaClinical Coding DetailsProvider Submission RequirementsMedication BackgroundQualifying DiagnosisInitial Jublia AuthorizationSubsequent Course AuthorizationRequired Prior TherapyTreatment Duration and Administration